These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 6323221)

  • 41. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
    Cody RJ
    Drugs; 1984 Aug; 28(2):144-69. PubMed ID: 6205842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different effects of two angiotensin converting enzyme inhibitors in primary hypertension--a comparison of captopril and enalapril.
    Karlberg BE; Sjöstrand A; Ohman KP
    J Hypertens Suppl; 1986 Dec; 4(5):S432-4. PubMed ID: 3033182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools].
    Modesti PA; Vanni S; Gensini GF
    Ital Heart J Suppl; 2003 Aug; 4(8):623-34. PubMed ID: 14655458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
    Frank GJ
    J Hypertens Suppl; 1989 Sep; 7(5):S17-22. PubMed ID: 2553900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
    Sweet CS
    Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Angiotensin-converting enzyme inhibition: side effects and risks].
    Schilling H; Scheler F
    Z Kardiol; 1988; 77 Suppl 3():47-54. PubMed ID: 2850687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A; Boner G; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension?
    Wu RA; Kailasam MT; Cervenka JH; Parmer RJ; Kennedy BP; Ziegler MG; O'Connor DT
    J Hypertens; 1994 Nov; 12(11):1243-7. PubMed ID: 7868871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [ACE inhibitors and their clinical significance].
    Brunner HR; Waeber B; Nussberger J
    Herz; 1987 Dec; 12 Suppl 1():3-9. PubMed ID: 3325394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Renal adaptation to a restriction of sodium intake in the rat: effects of inhibition of the renin-angiotensin system].
    Jover B; Dupont M; Casellas D; Mimran A
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1234-7. PubMed ID: 6098235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ACE inhibitors as initial therapy for hypertension.
    Schoenberger JA
    Am Fam Physician; 1988 Apr; 37(4):139-46. PubMed ID: 3282415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enalapril treatment in a patient with impaired renal function and intolerance to captopril.
    Lindsjö M; Danielson BG; Weiss L; Wikström B
    Scand J Urol Nephrol Suppl; 1984; 79():99-101. PubMed ID: 6089326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
    Atlas SA; Case DB; Yu ZY; Laragh JH
    Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Angiotensin converting enzyme inhibitors--a new group of hypotensive drugs].
    Lazowski J
    Wiad Lek; 1984 May; 37(10):792-6. PubMed ID: 6095537
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy of chronic heart failure with vasodilator agents].
    Zähringer J; Schultheiss HP
    Internist (Berl); 1986 May; 27(5):315-21. PubMed ID: 3015822
    [No Abstract]   [Full Text] [Related]  

  • 60. Angiotensin-converting enzyme inhibitors: a comparative review.
    Raia JJ; Barone JA; Byerly WG; Lacy CR
    DICP; 1990 May; 24(5):506-25. PubMed ID: 2188439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.